Investor Relations

Corporate Overview

CASI is an innovative biopharmaceutical company developing an anti-CD38 monoclonal antibody treatment for organ transplant rejection and autoimmune diseases.

View Presentation

Safe Harbor Information

Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including...

Read Full Statement

NASDAQ: CASI

0.00

CHANGE

0.00 0.00

VOLUME

0.00

52 WEEKS

0.00 - 0.00

DAY

0.00 - 0.00

Latest Releases

View All News

Analyst Coverage

CASI Pharmaceuticals, Inc. is followed by the analyst(s) listed below. This list is provided for information purposes only. Please note that any opinions, estimates or forecasts regarding CASI Pharmaceutical' s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of CASI Pharmaceuticals or its management. Analysts may be contacted directly for copies of their reports.

HC Wainwright & Co

Sean Lee

Slee@hcwco.com